Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $6.27 million. The enterprise value is -$3.69 million.
Important Dates
The last earnings date was Thursday, February 26, 2026, after market close.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REVB has 4.75 million shares outstanding. The number of shares has increased by 4,243.28% in one year.
| Current Share Class | 4.75M |
| Shares Outstanding | 4.75M |
| Shares Change (YoY) | +4,243.28% |
| Shares Change (QoQ) | +130.50% |
| Owned by Insiders (%) | 3.87% |
| Owned by Institutions (%) | 4.20% |
| Float | 4.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.24 |
| P/TBV Ratio | 0.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.41, with a Debt / Equity ratio of 0.08.
| Current Ratio | 5.41 |
| Quick Ratio | 5.36 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -131.38% and return on invested capital (ROIC) is -79.20%.
| Return on Equity (ROE) | -131.38% |
| Return on Assets (ROA) | -62.28% |
| Return on Invested Capital (ROIC) | -79.20% |
| Return on Capital Employed (ROCE) | -94.64% |
| Weighted Average Cost of Capital (WACC) | 3.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.65M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.94% in the last 52 weeks. The beta is -0.13, so REVB's price volatility has been lower than the market average.
| Beta (5Y) | -0.13 |
| 52-Week Price Change | -96.94% |
| 50-Day Moving Average | 2.59 |
| 200-Day Moving Average | 7.84 |
| Relative Strength Index (RSI) | 24.86 |
| Average Volume (20 Days) | 253,553 |
Short Selling Information
The latest short interest is 100,079, so 2.11% of the outstanding shares have been sold short.
| Short Interest | 100,079 |
| Short Previous Month | 258,211 |
| Short % of Shares Out | 2.11% |
| Short % of Float | 2.33% |
| Short Ratio (days to cover) | 0.06 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.07M |
| Pretax Income | -8.91M |
| Net Income | -14.87M |
| EBITDA | -9.04M |
| EBIT | -9.07M |
| Earnings Per Share (EPS) | -$23.95 |
Full Income StatementBalance Sheet
The company has $10.70 million in cash and $746,784 in debt, with a net cash position of $9.95 million or $2.10 per share.
| Cash & Cash Equivalents | 10.70M |
| Total Debt | 746,784 |
| Net Cash | 9.95M |
| Net Cash Per Share | $2.10 |
| Equity (Book Value) | 8.86M |
| Book Value Per Share | 5.59 |
| Working Capital | 8.81M |
Full Balance SheetCash Flow
| Operating Cash Flow | -8.27M |
| Capital Expenditures | n/a |
| Free Cash Flow | -8.27M |
| FCF Per Share | -$1.74 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
